NASDAQ · DXRHealthcareSurgical Instruments

Daxor financials

$11.70+3.08%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ4 '11
Dec 31
Q3 '11
Sep 30
Q2 '11
Jun 30
Q4 '10
Dec 31
Q3 '10
Sep 30
Q2 '10
Jun 30
Revenue$369.8K$340.9K$358.1K$361.4K$453.3K$368.3K
Gross profit$192.9K$191.5K$197.4K$176.7K$267.5K$202.9K
Gross margin52.2%56.2%55.1%48.9%59.0%55.1%
Operating income-$1.0M-$1.3M-$1.3M-$1.5M-$1.3M-$1.5M
Net income-$1.5M-$4.2M-$184.5K$2.3M$2.6M$188.4K
Net margin−403.2%−1227.2%−51.5%627.5%574.7%51.1%
Diluted EPS$-0.35$-0.99$-0.04$0.53$0.62$0.04
EBITDA-$934.3K-$1.2M-$1.3M-$1.5M-$1.2M-$1.5M
Operating cash flow$3.2M$3.3M—-$8.4M$2.6M—
Free cash flow$3.2M$3.3M—-$8.4M$2.5M—
Diluted shares4.2M4.2M4.2M4.2M4.2M4.2M

Balance sheet

Period endDec 31Sep 30Jun 30Dec 31
Cash & equivalents$59.6K$29.7K$111.8K$57.7K
Short-term investments$55.8M$52.3M$54.1M$53.9M
Total debt$37.2M$34.3M$38.0M$27.4M
Total assets$85.7M$88.3M$96.2M$91.2M
Total liabilities$49.5M$50.6M$50.7M$44.2M
Shareholders' equity$36.2M$37.6M$45.6M$47.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology